$ACOG.v Updates As Alpha Cognition (TSXV: ACOG) enters its next phase of growth, the company has appointed Don Kalkofen as CFO. Don has considerable experience in corporate finance, as well as a strong track record of successfully supporting the financing of clinical-stage biotech company development.
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/alpha-cognition-announces-change-of-cfo-grant-of-stock-options-and-addition-to-the-board-of-directors
$ACOG.v recently reported highly promising preclinical results for its ALPHA-0602 therapy designed to aid in the treatment of ALS. As the company continues to report promising trial data, its growth potential is becoming ever more apparent at this pre-revenue stage.
$ACOG.v is currently trading at $.98 and is valued at $60.27M.